$TMDX
TransMedics Group, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022008045 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $9.668M $30.26M $7.627M
YoY Change 26.76% 18.03% 25.92%
Cost Of Revenue $2.682M $9.103M $2.800M
YoY Change -4.21% 1.1% 20.69%
Gross Profit $6.986M $21.16M $4.828M
YoY Change 44.7% 27.2% 29.06%
Gross Profit Margin 72.26% 69.92% 63.3%
Selling, General & Admin $12.00M $38.28M $6.180M
YoY Change 94.17% 58.27% 0.16%
% of Gross Profit 171.77% 180.93% 128.0%
Research & Development $6.314M $22.30M $4.550M
YoY Change 38.77% 18.45% -27.32%
% of Gross Profit 90.38% 105.41% 94.24%
Depreciation & Amortization $466.0K $1.800M $430.0K
YoY Change 8.37% 12.5% 22.86%
% of Gross Profit 6.67% 8.51% 8.91%
Operating Expenses $18.31M $60.59M $10.72M
YoY Change 70.84% 40.84% -13.76%
Operating Profit -$11.33M -$39.43M -$5.896M
YoY Change 92.13% 49.44% -32.18%
Interest Expense -$1.323M -$4.751M -$410.0K
YoY Change 222.68% -219.22% -12.77%
% of Operating Profit
Other Income/Expense, Net -$4.751M $0.00
YoY Change 103.73%
Pretax Income -$12.65M -$44.18M -$6.300M
YoY Change 100.81% 53.85% -31.3%
Income Tax $17.00K $36.00K $10.00K
% Of Pretax Income
Net Earnings -$12.67M -$44.20M -$6.311M
YoY Change 100.73% 54.01% -31.23%
Net Earnings / Revenue -131.03% -146.06% -82.75%
Basic Earnings Per Share -$1.60
Diluted Earnings Per Share -$456.1K -$1.60 -$232.4K
COMMON SHARES
Basic Shares Outstanding 27.62M
Diluted Shares Outstanding 27.62M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $92.45M $92.45M $125.6M
YoY Change -26.39% -26.39% 525.12%
Cash & Equivalents $25.58M $25.58M $24.58M
Short-Term Investments $66.87M $66.87M $101.1M
Other Short-Term Assets $5.460M $5.460M $2.300M
YoY Change 137.39% 137.39% 53.33%
Inventory $14.86M $14.86M $11.93M
Prepaid Expenses
Receivables $5.934M $5.934M $6.864M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $118.7M $118.7M $146.8M
YoY Change -19.12% -19.14% 46.76%
LONG-TERM ASSETS
Property, Plant & Equipment $9.841M $15.69M $4.754M
YoY Change 107.0% 226.83% -0.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K $6.000K
YoY Change 8233.33% 0.0% 0.0%
Total Long-Term Assets $16.19M $16.19M $5.260M
YoY Change 207.76% 211.31% -0.72%
TOTAL ASSETS
Total Short-Term Assets $118.7M $118.7M $146.8M
Total Long-Term Assets $16.19M $16.19M $5.260M
Total Assets $134.9M $134.9M $152.0M
YoY Change -11.27% -11.25% 44.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.651M $6.651M $1.206M
YoY Change 451.49% 454.25% -83.36%
Accrued Expenses $16.34M $16.34M $10.30M
YoY Change 58.61% 58.61% 24.1%
Deferred Revenue $250.0K $263.0K
YoY Change -4.94% 58.43%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.24M $23.24M $11.88M
YoY Change 95.62% 95.28% -26.29%
LONG-TERM LIABILITIES
Long-Term Debt $35.20M $35.20M $34.66M
YoY Change 1.56% 1.43% 1.5%
Other Long-Term Liabilities $8.604M $8.604M $1.600M
YoY Change 437.75% 437.75% 300.0%
Total Long-Term Liabilities $35.20M $43.80M $34.66M
YoY Change 1.56% 20.66% 1.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.24M $23.24M $11.88M
Total Long-Term Liabilities $35.20M $43.80M $34.66M
Total Liabilities $67.04M $67.04M $48.14M
YoY Change 39.27% 39.37% -4.97%
SHAREHOLDERS EQUITY
Retained Earnings -$442.4M
YoY Change
Common Stock $510.5M $502.2M
YoY Change 1.65% 18.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.85M $67.85M $103.9M
YoY Change
Total Liabilities & Shareholders Equity $134.9M $134.9M $152.0M
YoY Change -11.25% -11.25% 44.35%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$12.67M -$44.20M -$6.311M
YoY Change 100.73% 54.01% -31.23%
Depreciation, Depletion And Amortization $466.0K $1.800M $430.0K
YoY Change 8.37% 12.5% 22.86%
Cash From Operating Activities -$6.648M -$28.86M -$7.140M
YoY Change -6.89% -4.63% -1.79%
INVESTING ACTIVITIES
Capital Expenditures -$3.178M $3.519M -$10.00K
YoY Change 31680.0% 673.41% -200.0%
Acquisitions
YoY Change
Other Investing Activities $13.17M $32.79M $9.890M
YoY Change 33.16% -179.69% 34.74%
Cash From Investing Activities $9.992M $29.27M $9.880M
YoY Change 1.13% -170.36% 34.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 45.00K 1.393M 30.00K
YoY Change 50.0% -98.16% -112.0%
NET CHANGE
Cash From Operating Activities -6.648M -28.86M -7.140M
Cash From Investing Activities 9.992M 29.27M 9.880M
Cash From Financing Activities 45.00K 1.393M 30.00K
Net Change In Cash 3.389M 999.0K 2.770M
YoY Change 22.35% -77.75% -1831.25%
FREE CASH FLOW
Cash From Operating Activities -$6.648M -$28.86M -$7.140M
Capital Expenditures -$3.178M $3.519M -$10.00K
Free Cash Flow -$3.470M -$32.38M -$7.130M
YoY Change -51.33% 5.41% -2.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 tmdx Term Of Product Warranties
TermOfProductWarranties
P1Y
CY2021Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2019Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26080000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27961954
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Minuteman Road
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Andover
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01810
CY2021 dei City Area Code
CityAreaCode
978
CY2021 dei Local Phone Number
LocalPhoneNumber
552-0900
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021Q2 dei Entity Public Float
EntityPublicFloat
857800000
CY2021 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2027-12-31
CY2021 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.60
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27616839
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24702764
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M19D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M14D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M14D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M9D
CY2021 dei Entity File Number
EntityFileNumber
001-38891
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2181531
CY2021 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25580000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24581000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
66872000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
101061000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5934000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6864000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14859000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11934000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5460000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
118705000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
146766000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9841000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4754000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5847000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6651000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1206000
CY2021Q4 us-gaap Assets
Assets
134893000
CY2020Q4 us-gaap Assets
Assets
152026000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16337000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10410000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
250000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
263000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8604000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-877000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4751000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44179000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28716000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
36000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-44215000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.60
CY2020 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-933000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27616839
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24702764
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-44215000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28748000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-46000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44308000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28841000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54649000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
227000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
357000
CY2020 tmdx Discounts And Stock Issuance Costs
DiscountsAndStockIssuanceCosts
585000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75085000
CY2020 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2414000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28748000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
103891000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
974000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
419000
CY2021 tmdx Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6878000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-44215000
CY2021 us-gaap Profit Loss
ProfitLoss
-44215000
CY2020 us-gaap Profit Loss
ProfitLoss
-28748000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1817000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1577000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6878000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2414000
CY2021 tmdx Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
540000
CY2020 tmdx Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
511000
CY2021 tmdx Non Cash Lease Expense
NonCashLeaseExpense
829000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1356000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
634000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-928000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1065000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-840000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
218000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4894000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1740000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3151000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
769000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5090000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5802000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4875000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1948000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
60000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
236000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-28700000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28864000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30265000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3519000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
455000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
72024000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
121793000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
104810000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
80650000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29267000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41598000
CY2020 tmdx Proceeds From Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Commissions
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissions
75670000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
705000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
974000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
227000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
419000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
357000
CY2020 tmdx Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
2249000
CY2020 tmdx Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
2249000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1393000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75549000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-797000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
803000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
999000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4489000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25081000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20592000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25081000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
3334000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
3475000
CY2021 tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
1823000
CY2020 tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
1191000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1200000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25580000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24581000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
500000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26080000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25081000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-44200000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-442400000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
92500000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. <span style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. </span><span style="color:#000000;">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. </span>Actual results may differ from those estimates or assumptions. </p>
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
101061000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk of Concentrations of Credit, Significant Customers and Significant Suppliers </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company has not experienced any other-than-temporary losses with respect to its cash, cash equivalents and marketable securities and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that accounted for <span>10%</span> or more of the Company’s net revenue or accounts receivable. For the year ended December 31, 2021, one customer accounted for 11% of net revenue. For the year ended December 31, 2020, two customers accounted for 14% and 10% of net revenue, respectively. As of December 31, 2021, two customers accounted for 21% and 15% of accounts receivable, respectively. As of December 31, 2020, one customer accounted for 30% of accounts receivable.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships. </p>
CY2021 tmdx Number Of Letters Of Credit Maintained
NumberOfLettersOfCreditMaintained
2
CY2020 tmdx Number Of Letters Of Credit Maintained
NumberOfLettersOfCreditMaintained
2
CY2021Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
500000
CY2020Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
500000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26100000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25100000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2021 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Capitalized Software Development Costs For Software Sold To Customers
CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers
0
CY2020Q4 us-gaap Capitalized Software Development Costs For Software Sold To Customers
CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers
0
CY2021 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
The Company provides a one-year warranty on its OCS Consoles and disposable sets and replaces or repairs any OCS Console or disposable set that does not function in accordance with the product specifications
CY2021Q4 us-gaap Provision For Loss On Contracts
ProvisionForLossOnContracts
0
CY2021 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2020 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2874455
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2340625
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
66908000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
66872000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
101050000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78041000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
114890000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7274000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6770000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1932000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1102000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5653000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4062000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14859000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11934000
CY2021 tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
1800000
CY2020 tmdx Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
1200000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19576000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12781000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9735000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8027000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9841000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4754000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1800000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1600000
CY2021Q4 tmdx Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
4567000
CY2020Q4 tmdx Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
4426000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5173000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4030000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1973000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4624000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1610000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16337000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10410000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2021Q4 tmdx Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
35000000
CY2020Q4 tmdx Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
35000000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
511000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
834000
CY2021Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
708000
CY2020Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
491000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35197000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34657000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0090
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0091
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.54
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2261234
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.17
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26671000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1326675
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.60
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
588461
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.65
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
200060
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
28.10
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1838
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
31.76
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2797550
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.64
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14625000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2797550
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.64
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14625000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1371048
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.80
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13143000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
16300000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2900000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.63
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.91
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6878000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2414000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20900000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-44321000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28803000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
142000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
87000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44179000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28716000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.069
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.024
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.036
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.032
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.017
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.078
CY2021 tmdx Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
-0.011
CY2020 tmdx Effective Income Tax Rate Reconciliation Return To Provision
EffectiveIncomeTaxRateReconciliationReturnToProvision
-0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.343
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
94672000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81390000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4291000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6136000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12186000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11541000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2528000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1390000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2254000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
791000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
79000
CY2021Q4 tmdx Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
2299000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
170000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
132000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
118400000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101459000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
674000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
218000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1562000
CY2020Q4 tmdx Deferred Tax Liabilities Unrealized Gain Loss
DeferredTaxLiabilitiesUnrealizedGainLoss
212000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2236000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
430000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
116164000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101029000
CY2021 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15100000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101029000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
95024000
CY2021 tmdx Deferred Tax Assets Valuation Allowance Increases Recorded To Income Tax Provision
DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision
15135000
CY2020 tmdx Deferred Tax Assets Valuation Allowance Increases Recorded To Income Tax Provision
DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision
6005000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
116164000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101029000
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
that expire in December 2027 and include a lease incentive, fixed payment escalations, and rent holidays. The Leases include an option to renew for an additional five years.
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021 tmdx Lease Base Rent Annual Increase
LeaseBaseRentAnnualIncrease
0.025
CY2021Q4 tmdx Leasehold Improvements Landlord Allowance
LeaseholdImprovementsLandlordAllowance
3400000
CY2021Q4 us-gaap Incentive To Lessee
IncentiveToLessee
3400000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1353000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
159000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
640000
CY2021 us-gaap Lease Cost
LeaseCost
2152000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1901000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.067
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1948000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1997000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2047000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2098000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2150000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
2204000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
12444000
CY2021Q4 tmdx Lessee Operating Lease Liability Undiscounted Excess Amount Imputed Interest
LesseeOperatingLeaseLiabilityUndiscountedExcessAmountImputedInterest
2273000
CY2021Q4 tmdx Lessee Operating Lease Liability Undiscounted Excess Amount Lease Incentives
LesseeOperatingLeaseLiabilityUndiscountedExcessAmountLeaseIncentives
1567000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8604000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8604000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8604000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1900000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1948000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1997000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2047000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2098000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4354000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14344000
CY2021 us-gaap Payments For Royalties
PaymentsForRoyalties
400000
CY2020 us-gaap Payments For Royalties
PaymentsForRoyalties
300000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
200000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
100000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021Q1 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
9500000
CY2021Q1 tmdx Recorded Unconditional Purchase Commitment Maturity Year And Month
RecordedUnconditionalPurchaseCommitmentMaturityYearAndMonth
2029-12
CY2021Q4 tmdx Unconditional Purchase Obligation Remaining Amount
UnconditionalPurchaseObligationRemainingAmount
8000000.0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Revenues
Revenues
30262000
CY2020 us-gaap Revenues
Revenues
25639000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
9841000
CY2020Q4 us-gaap Noncurrent Assets
NoncurrentAssets
4754000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31385000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28356000
CY2021 tmdx Clinical Trial Expense
ClinicalTrialExpense
1123000
CY2020 tmdx Clinical Trial Expense
ClinicalTrialExpense
2717000
CY2021 us-gaap Revenues
Revenues
30262000
CY2020 us-gaap Revenues
Revenues
25639000
CY2021 tmdx Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
2100000
CY2020 tmdx Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
1600000
CY2021 us-gaap Revenues
Revenues
30262000
CY2020 us-gaap Revenues
Revenues
25639000
CY2021 us-gaap Revenues
Revenues
30262000
CY2020 us-gaap Revenues
Revenues
25639000

Files In Submission

Name View Source Status
0001564590-22-008045-index-headers.html Edgar Link pending
0001564590-22-008045-index.html Edgar Link pending
0001564590-22-008045.txt Edgar Link pending
0001564590-22-008045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gpfa2oc5aycg000001.jpg Edgar Link pending
gpfa2oc5aycg000002.jpg Edgar Link pending
gpfa2oc5aycg000003.jpg Edgar Link pending
gpfa2oc5aycg000004.jpg Edgar Link pending
gpfa2oc5aycg000005.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmdx-10k_20211231.htm Edgar Link pending
tmdx-10k_20211231_htm.xml Edgar Link completed
tmdx-20211231.xsd Edgar Link pending
tmdx-20211231_cal.xml Edgar Link unprocessable
tmdx-20211231_def.xml Edgar Link unprocessable
tmdx-20211231_lab.xml Edgar Link unprocessable
tmdx-20211231_pre.xml Edgar Link unprocessable
tmdx-ex231_6.htm Edgar Link pending
tmdx-ex311_7.htm Edgar Link pending
tmdx-ex312_8.htm Edgar Link pending
tmdx-ex321_10.htm Edgar Link pending
tmdx-ex322_9.htm Edgar Link pending